medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 1

<< Back Next >>

Ann Hepatol 2016; 15 (1)

Risk factors for and management of ischemic-type biliary lesions following orthotopic liver transplantation: A single center experience

Jiang T, Chuanyun L, Duan B, Yuan L, Wang L, Shichun L

Language: English
References: 37
Page: 41-46
PDF size: 142.72 Kb.


ABSTRACT

Introduction. Biliary complications can cause morbidity, graft loss, and mortality after liver transplantation. The most troublesome biliary complications are ischemic-type biliary lesions (ITBL), which occur since transplants can now be performed after the donor has undergone circulatory death. The exact origin of this type of biliary complication remains unknown. Material and methods. A total of 528 patients were retrospectively analyzed following liver transplantation after excluding 30 patients with primary sclerosing cholangitis and those lost to follow-up from January 2007 to January 2014. The incidence of and risk factors for ITBL were evaluated. Results. Cold ischemia time (CIT) (P = 0.042) and warm ischemia time (WIT) (P = 0.006) were found to be independent risk factors for the development of ITBL. Use of the cytochrome P450 (CYP) 3A5 genotype assay to guide individualization of immunosuppressive medications resulted in significantly fewer ITBL (P = 0.027. Autoimmune hepatitis might be a risk factor for ITBL, as determined using univariate analysis (P = 0.047). Conclusions. Efforts should be taken to minimize risk factors associated with ITBL, such as CIT and WIT. The CYP3A5 genotype assay should be used to guide selection of immunosuppressive therapy in an effort to reduce the occurrence of ITBL.


REFERENCES

  1. Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, Waddell WR. Homotransplantation of the liver in humans. Surg Gynecol Obstet 1963; 117:659-76. PubMed:14100514.

  2. Lerut J, Gordon RD, Iwatsuki S, Esquivel CO, Todo S, Tzakis A, Starzl TE. Biliary tract complications in human orthotopic liver transplantation. Transplantation 1987; 43: 47-51. PubMed:3541321.

  3. Calne RY. A new technique for biliary drainage in orthotopic liver transplantation utilizing the gall-bladder as a pedicle graft conduit between the donor and recipient common bile ducts. Ann Surg 1976; 184: 605-09. PubMed:791164.

  4. Mourad MM, Algarni A, Liossis C, Bramhall SR. Aetiology and risk factors of ischaemic cholangiopathy after liver transplantation. World J Gastroenterol 2014; 28(20): 6159-69. PubMed:24876737.

  5. O’Neill S, Roebuck A, Khoo E, Harrison EM. A meta-analysis and meta-regression of outcomes including biliary complications in donation after cardiac death liver transplantation. Transpl Int 2014; 27: 1159-74. PubMed:25052036.

  6. Sanchez-Urdazpal L, Gores GJ, Ward EM, Maus TP, Wahlstrom HE, Moore SB, Wiesner RH, et al. Ischemictype biliary complications after orthotopic liver transplantation. Hepatology 1992; 16: 49-53. PubMed:1618482.

  7. Zhang X, Wang Z, Fan J, Liu G, Peng Z. Impact of interleukin- 10 genepolymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period. Eur J Clin Pharmacol 2011; 67: 803-13. PubMed:21359536.

  8. Jacobson PA, Oetting WS, Brearley AM, Leduc R, Guan W, Schladt D, Matas AJ, et al. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation 2011; 91: 300-08. PubMed:21206424.

  9. Tang HL, Xie HG, Yao Y, Hu YF. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers. Pharmacogenet Genomics 2011; 21: 713-20. PubMed:21886016.

  10. Uesugi M, Masuda S, Katsura T, Oike F, Takada Y, Inui K. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics 2006; 16: 119-27. PubMed:16424824.

  11. Rojas LE, Herrero MJ, Bosó V, García-Eliz M, Poveda JL, Librero J, Aliño SF. Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A > G genotype on tacrolimus dose requirements in liver transplantation. Pharmacogenet Genomics 2013; 23: 509-17. PubMed:23873120.

  12. Fisher A, Miller CH. Ischemic-type biliary strictures in liver allografts: the Achilles heel revisited? Hepatology 1995; 21: 589-91. PubMed:7843733.

  13. Foley DP, Fernandez LA, Leverson G, Anderson M, Mezrich J, Sollinger HW, D’Alessandro A. Biliary complications after liver transplantation from donation after cardiac death donors an analysis of risk factors and long-term outcomes from a single center. Ann Surg 2011; 253: 817-25. PubMed:21475025.

  14. Jay CL, Lyuksemburg V, Ladner DP, Wang E, Caicedo JC, Holl JL, Abecassis MM, et al. Ischemic cholangiopathy after controlled donation after cardiac death liver transplantation: a meta-analysis. Ann Surg 2011; 253: 259-64. PubMed:21245668.

  15. Sanchez-Urdazpal L, Gores GJ, Ward EM, Galle PR, Neurath MF. Diagnostic features and clinical outcome of ischemictype biliary lesions. Hepatology 1993; 17: 605-9. PubMed:18404601.

  16. Thethy S, Thomson BNJ, Pleass H, Wigmore SJ, Madhavan K, Akyol M, Forsythe JL, et al. Management of biliary tract complications after orthotopic liver transplantation. Clin Transplant 2004; 18: 647-53. PubMed:15516238.

  17. Heidenhain C, Pratschke J, Puhl G, Neumann U, Pascher A, Veltzke-Schlieker W, Neuhaus P. Incidence of and risk factors for ischemic-type biliary lesions following orthotopic liver transplantation. Transpl Int 2010; 23: 14-22. PubMed:19691661.

  18. Sheng R, Campbell WL, Zajko AB, Baron RL. Cholangiographic features of biliary strictures after liver transplantation for primary sclerosing cholangitis: evidence of recurrent disease. AJR 1996; 166: 1109-13. PubMed:8615253.

  19. Jeyarajah DR, Netto GJ, Lee SP, Testa G, Abbasoglu O, Husberg BS, Levy MF, et al. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process? Transplantation 1998; 66: 1300-6. PubMed:9846512.

  20. Graziadei IW, Wiesner RH, Batts KP, Marotta PJ, LaRusso NF, Porayko MK, Hay JE, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 1999; 29: 1050-6. PubMed:10094945.

  21. Guichelaar MM, Benson JT, Malinchoc M, Krom RA, Wiesner RH, Charlton MR. Risk factors for and clinical course of nonanastomotic biliary strictures after liver transplantation. Am J Transplant 2003; 3: 885-90. PubMed:21814481.

  22. Sanchez-Urdazpal L, Gores GJ, Ward EM, Hay E, Buckel EG, Wiesner RH, Krom RA. Clinical outcome of ischemic-type biliary complications after liver transplantation. Transplant Proc 1993; 25(1 Pt. 2): 1107-9. PubMed:8442058.

  23. Frongillo F, Grossi U, Avolio AW, Sganga G, Nure E, Pepe G, Bianco G, et al. Factors predicting ischemic-type biliary lesions (ITBLs) after liver transplantation. Transplant Proc 2012; 44: 2002-04. PubMed:22974892.

  24. Caldwell-Kenkel JC, Currin RT, Tanaka Y, Thurman RG, Lemasters JJ. Reperfusion injury to endothelial cells following cold ischemic storage of rat livers. Hepatology 1989; 10: 292-99. PubMed:2668147.

  25. Henrion J. Ischemia/reperfusion injury of the liver: pathophysiologic hypotheses and potential relevance to human hypoxic hepatitis. Acta Gastroenterol Belg 2000; 63: 336-47. PubMed:11233516.

  26. Tillou X, Thuret R, Doerfler A, CTAFU. Ischemia/reperfusion during normothermic perfusion. Prog Urol 2014; 24(Suppl. 1): S51-S55. PubMed:24950934.

  27. Bellomo R, Marino B, Starkey G, Fink M, Wang BZ, Eastwood GM, Peck L, et al. Extended normothermic extracorporeal perfusion of isolated human liver after warm ischaemia: a preliminary report. Crit Care Resusc 2014; 16: 197-201. PubMed:25161022.

  28. Graziadei IW. Recurrence of nonviral liver diseases after liver transplantation. Clin Liver Dis 2014; 18: 675-85. PubMed:25017083.

  29. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006; 12: 1813-24 [PubMed:17031826].

  30. Rull R, Garcia Valdecasas JC, Grande L, Fuster J, Lacy AM, González FX, Rimola A, et al. Intrahepatic biliary lesions after orthotopic liver transplantation. Transpl Int 2001; 14: 129- 34. PubMed:11499901.

  31. Moench C, Uhrig A, Lohse AW, Otto G. CC chemokine receptor 5delta32 polymorphism-a risk factor for ischemic-type biliary lesions following orthotopic liver transplantation. Liver Transpl 2004; 10: 434-39. PubMed:15004773.

  32. Urbani L, Mazzoni A, Bianco I, Grazzini T, De Simone P, Catalano G, Montin U, et al. The role of immunomodulation in ABO-incompatible adult liver transplant recipients. J Clin Apher 2008; 23: 55-62. PubMed:18186527.

  33. Nishida S, Nakamura N, Kadono J, Komokata T, Sakata R, Madariaga JR, Tzakis AG. Intrahepatic biliary strictures after liver transplantation. J Hepatobiliary Pancreat Surg 2006; 13: 511-16. PubMed:17139424.

  34. Scotté M, Dousset B, Calmus Y, Conti F, Houssin D, Chapuis Y. The influence of cold ischemia time on biliary complications following liver transplantation. J Hepatol 1994; 21: 340-46. PubMed:7836702.

  35. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43: 623-53. PubMed:15244495.

  36. Chen D, Fan J, Guo F, Qin S, Wang Z, Peng Z. Novel single nucleotide polymorphisms in interleukin 6 affect tacrolimus metabolism in liver transplant patients. PLoS One 2013; 8: e73405. PubMed:23991193.

  37. Yoon SH, Cho JH, Kwon O, Choi JY, Park SH, Kim YL, Yoon YR, et al. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).Transplantation 2013; 95: 828- 34. PubMed:23364483.




2020     |     www.medigraphic.com